Adam S. Kibel, MD, Author at Grand Rounds in Urology

Adam S. Kibel, MD

Brigham and Women's Hospital

Boston, Massachusetts

Adam S. Kibel, MD, is the DiNovi Family Distinguished Chair of Urology at Brigham and Women’s Hospital and Dana-Farber Brigham and Women’s Cancer Center in Boston, Massachusetts. Dr. Kibel is also the Elliott Carr Cutler Professor of Surgery at Harvard Medical School, and Chairman of the Harvard Urology Residency Program. His clinical interests include genetics of prostate cancer, minimally-invasive surgical treatments for urologic cancers, and robotic surgery for urologic cancers.

Dr. Kibel received his undergraduate and medical degrees from Cornell University Medical School. Dr. Kibel completed his urology residency at the Harvard Urology Program and his fellowship at the Brady Urologic Institute at John Hopkins.

Dr. Kibel has been listed as one of America’s Top Doctors by Castle Connolly and was named a top urologist by Boston magazine for his work on minimally invasive treatments for urologic cancers. Dr. Kibel has authored over 250 peer-reviewed publications on his research, with topics including the identification of molecular markers of urologic tumors, adjuvant and neoadjuvant approaches to treatment of aggressive disease and improved imaging of patients with urologic malignancies. Dr. Kibel’s research has been supported by the National Cancer Institute, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease.

Talks by Adam S. Kibel, MD

Neoadjuvant Therapy for High-Risk Prostate Cancer

Posted by Adam S. Kibel, MD | Aug 2019

Adam S. Kibel, MD, argues that, while it is common to debate the best intervention method for local prostate cancer, there also must be an emphasis on the systemic treatment of micro-metastatic disease in the interest of decreasing disease-specific death. He then reviews the impact of timing, duration, and intensity of systemic therapy on patient outcomes, focusing on four trials evaluating neoadjuvant therapy for high-risk prostate cancer.